CHMP Clears GSK's Severe Asthma Drug In Europe
This article was originally published in Scrip
Executive Summary
The EMA's CHMP has issued a positive opinion recommending marketing approval for GlaxoSmithKline's mepolizumab, which is to be sold under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.